1. Crohn's disease patients treated with adalimumab benefit from co-treatment with immunomodulators: Table 1
- Author
-
Martijn G.H. van Oijen, Bas Oldenburg, Marije J. Ammerlaan, Mirthe E. van der Valk, and Peter D. Siersema
- Subjects
musculoskeletal diseases ,medicine.medical_specialty ,Crohn's disease ,biology ,medicine.drug_class ,business.industry ,Immunogenicity ,Gastroenterology ,medicine.disease ,Monoclonal antibody ,Infliximab ,Maintenance therapy ,Internal medicine ,Concomitant ,Immunology ,medicine ,Adalimumab ,biology.protein ,Antibody ,skin and connective tissue diseases ,business ,medicine.drug - Abstract
We read with interest the study by Sokol et al in Gut , emphasising the need for co-treatment with immunomodulators in patients receiving infliximab maintenance therapy. Concomitant use of immunosuppressives was associated with reduced disease activity and infliximab dose escalation, presumably through a lowered frequency of antibody formation.1 Although adalimumab is a 100% human anti-tumour necrosis factor monoclonal antibody, it is not devoid of immunogenicity. Antibodies against adalimumab have been reported in 2.6–38% of patients treated for Crohn's disease or rheumatoid arthritis.2 However, the long-term efficacy of the combination of adalimumab plus immunosuppressives in this setting is not known. One observational study from Karmiris et al performed at …
- Published
- 2011
- Full Text
- View/download PDF